Benchmark Maintains Buy on Ultralife, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Josh Sullivan maintains a Buy rating on Ultralife (NASDAQ:ULBI) and raises the price target from $13 to $14.
June 27, 2024 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Josh Sullivan maintains a Buy rating on Ultralife and raises the price target from $13 to $14.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100